Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

Annovis Bio, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Their primary product, ...